Notes to editor
This press release accompanies both a presentation and a press conference at ESC Congress 2025.
It does not necessarily reflect the opinion of the European Society of Cardiology.
ESC Press Office
Tel: +33 6 61 40 18 84
Email: press@escardio.org
Follow European Society of Cardiology News on LinkedIn
The hashtag for ESC Congress 2025 is #ESCCongress
Journalists are invited to become accredited and register here.
Check out the ESC Media and Embargo Policy.
Funding: The trial was funded by Bristol Myers Squibb.
Disclosures: Professor Desai reports consultant and research agreements with Bristol Myers Squibb, Edgewise, Viz AI, Tenaya and Cytokinetics.
References and notes:
1‘ODYSSEY-HCM: Mavacamten in nHCM’ presented during HOT LINE 2 on 30 August 2025 at 09:08 to 09:18 in Madrid (Main Auditorium) and simultaneously published in New England Journal of Medicine
2Ho CY, Mealiffe ME, Bach RG, et al. Evaluation of mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2020;75:2649–2660.
3’Cardiac biomarkers on mavacamten in nonobstructive HCM: Sub-study of the ODYSSEY-HCM trial’ will be presented in the New perspectives in cardiology – the precision care of myocardial disease session on 31 August 2025 at 15:15 to 16:00 in the Discovery Pole (North Convention Centre).
4’Echocardiographic changes in nonobstructive hypertrophic cardiomyopathy patients treated with mavacamten: A sub-study of the ODYSSEY-HCM trial’ will be presented in the Hypertrophic cardiomyopathy: from gene to treatment session on 31 August 2025 at 18:00 to 18:10 in Science Box 4 (Research Gateway).
About ESC Congress 2025
It is the world’s largest gathering of cardiovascular professionals, disseminating ground-breaking science both onsite in Madrid and online – from 29 August to 1 September 2025. Explore the scientific programme. More information is available from the ESC Press Office at press@escardio.org.
About the European Society of Cardiology
The ESC brings together healthcare professionals from more than 150 countries, working to advance cardiovascular medicine and help people to live longer, healthier lives.